Introduction
Borderline personality disorder is a severe mental disorder that has its onset during adolescence and emerging adulthood. 1 It affects up to 3% of the population 2,3 and occurs almost equally among males and females. 4 The disorder has a fourfold higher prevalence among primary care patients than among the general population. 5 It affects around one-quarter of primary care patients with depression 6 and one in five psychiatric outpatients. 7, 8 In these settings females outnumber males by a ratio of up to 4:1.
Borderline personality disorder is a leading contributor to the burden of disease in our community. It is associated with adverse longterm outcomes that include severe and persistent functional disability, 9 high family and carer burden, 10 physical ill health, 11 and premature mortality, 12 including a suicide rate of 8%. 13 People with the disorder use mental health services continuously for long periods of time. 14 After schizophrenia, borderline personality disorder is the most costly psychiatric disorder to treat in Australia on a per case basis. 15 Psychosocial treatment is the primary therapy but access to this is poor. Despite the effectiveness of treatment, persisting psychopathology (e.g. borderline personality disorder features, depressive and anxiety symptoms) and functional impairment remain clinically problematic.
A common cause of misdiagnosis of borderline personality disorder is to rely on 'gut feeling' when a patient presents as interpersonally abrasive, sullen or hostile, particularly if the individual also engages in self-harm. Such diagnoses are often unreliable because they do not assess each of the DSM-5 borderline personality disorder criteria and do not take into account other reasons for such presentations, such as temporary aberrations in mental state, depression or other disorders.
Another cause of diagnostic confusion is the high rate of comorbid conditions. Comorbidity with other personality disorders and with mental state disorders is the norm. At times, these other disorders (e.g. mood, anxiety, eating and substance use disorders) can overwhelm the clinical picture, but this does not indicate that the underlying personality pathology is unimportant or should be a secondary concern. 21 Rather, there is evidence to suggest that personality disorder might be a key vulnerability factor for recurrent mental state disorders. 22, 23 Patients with borderline personality disorder who have these co-occurring conditions should be treated for these conditions in accordance with best practice. However, there should not be a disproportionate emphasis given to the immediate relief of mental state pathology at the expense of managing the borderline personality disorder.
Treatment
Since the 1990s there has been growing optimism and enthusiasm for the treatment of borderline personality disorder. There is now a variety of effective evidencebased psychosocial treatments (Box 2). Referral for one of these first-line treatments is recommended. 16, 24 No single treatment is recommended over another and they have common core features (Box 2). 25 Treatment guidelines include one published by the Australian National Health and Medical Research Council (NHMRC). 16 Despite advances in psychosocial treatment for borderline personality disorder, improvements remain suboptimal. 24, 25 Access to treatment is limited, and dropout rates are high (15-77%). 26 The NHMRC guidelines provide advice that can be implemented when referral to specialist services for borderline personality disorder is unavailable.
Evidence for drug therapy
Pharmacotherapy has been investigated as a standalone or adjunctive treatment option for borderline personality disorder. There are many high-quality reviews 16, 27, 28 including a Cochrane review. 27, 29 The Cochrane group found 33 randomised controlled trials in adults with borderline personality disorder, 27, 29 
Assessment
The DSM-5 criteria for borderline personality disorder are listed in Box 1. 18 Although the DSM-5 requires any five of these nine criteria in order to make a diagnosis, even low levels of borderline pathology (e.g. one criterion) are associated with substantial increases in psychosocial impairment. 19 Despite the evidence of the reliability and validity of the diagnosis, and the treatability of the condition, 20 many people with borderline personality disorder remain undiagnosed in clinical practice. This places them at risk of being given treatments that are ineffective or even harmful. 21 The central task for diagnosing personality disorder is to separate 'state' (transient aberrations in mental state) from 'trait' (long-standing patterns of thinking, feeling, behaving, perceiving and relating). Many mental state disorders can present with features that are similar to borderline personality disorder. For example, affective dysregulation is characteristic of both bipolar disorder and borderline personality disorder. Also, the current definition of depression incorporates non-specific forms of dysphoria that overlap with borderline personality disorder. What distinguishes borderline personality from these other disorders is that the features are present most of the time and comprise part of the patient's 'usual self'. These patients will tell you that this is how they 'usually are'. Although various tools are available to aid the diagnosis of borderline personality disorder, clinical application of the DSM-5 criteria is sufficient in a busy clinical practice. Each of the nine criteria should be enquired about and considered in turn.
Box 1 Diagnostic criteria for borderline personality disorder 18
A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity, beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following: 
Guidelines
In light of the clinical needs and pressures, and the harm associated with prescribing for these patients, the NHMRC 16 and UK National Institute for Health and Care Excellence (NICE) 28 have considered the controlled trial evidence. In general, both groups recommend against prescribing psychotropic drugs for treating borderline personality disorder. Importantly, the NHMRC guideline recognises that the absence of evidence can lead to heterogeneity of practice. It therefore provides some guidance for those who wish to try empirical treatment (Box 3).
but commented that the overall evidence base for prescribing is unsatisfactory. The literature is hampered by small trials (less than 50 patients) of numerous drugs, short treatment periods (mean duration of 12 weeks), diverse outcome measures, infrequent replication of findings, and lack of independence from the pharmaceutical industry. 30, 31 In addition, controversy has surrounded the methods of one research group and the integrity of the findings. 29 The available evidence 16 • People with borderline personality disorder should be provided with structured psychological therapies that are specifically designed for borderline personality disorder, and conducted by one or more adequately trained and supervised health professionals.
• Drugs should not be used as primary therapy for borderline personality disorder, because they have only modest and inconsistent effects, and do not change the nature and course of the disorder.
• The time-limited use of drugs can be considered as an adjunct to psychological therapy, to manage specific symptoms.
• Caution should be used if prescribing drugs that may be lethal in overdose, because of high suicide risk with prescribed drugs in people with borderline personality disorder.
• Caution should be used if prescribing medicines associated with substance dependence.
• Before starting time-limited pharmacotherapy for people with borderline personality disorder:
-ensure that a drug is not used in place of other more appropriate interventions -take account of the psychological meaning of prescribing (both for the individual and for the prescriber) and the impact that prescribing decisions may have on the therapeutic relationship and the overall borderline personality disorder management plan, including long-term treatment strategies -use a single drug and avoid polypharmacy if possible -ensure that there is consensus among prescribers about the drug used, and collaboration with other health professionals involved in the person's care, and that the main prescriber is identified -establish likely risks of prescribing, including interactions with alcohol and other substances.
• The use of drugs can be considered in acute crisis situations where psychological approaches are not sufficient.
• If drugs have been prescribed to manage a crisis, they should be withdrawn once the crisis is resolved.
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Full text free online at nps.org.au/australianprescriber Clinicians need to be aware of their own limits and needs and should be willing to communicate these to the patient, rather than dress them up as the patient's needs. For example, the doctor's responsibility to prescribe safely, legally and ethically might be at odds with the patient's demands for immediate relief from distressing symptoms.
Clinicians also need to admit and be willing to openly discuss difficulties. It is often much easier to start prescribing than to stop it. Honest and open discussion about whether a trial of a drug is warranted or has been effective is fundamental.
Conclusion
Borderline personality disorder is a leading cause of disability and mortality and is common in clinical practice. Although it was once considered 'untreatable', the outlook for patients with borderline personality disorder is much improved, with a range of effective psychosocial treatments available for the disorder. However, access to these treatments is limited in the Australian healthcare system. Despite this, drugs should not be used as primary therapy for borderline personality disorder because they have only modest and inconsistent effects. They do not change the nature or course of the disorder. A time-limited trial of a drug can be considered as an adjunct to psychological therapy, to manage specific symptoms, but caution is needed. The introductory chapters cover technical and pharmaceutical issues with tubes, drugs and administration, as well as tube blockage, drug errors and occupational exposure.
The monographs list UK formulations and relevant data for each drug. Information is provided on sites of oral absorption, alternative routes, interactions with food and enteral feeds, health and safety precautions, altering available products, and intragastric and intrajejunal administration procedures.
The products listed may differ from those available in Australia. The print is very small, and the book does not cover administration to patients with swallowing difficulties. A publication by the Society of Hospital Pharmacists of Australia, the Australian Don't Rush to Crush Handbook, covers administration via enteral tubes in less detail, but includes information on swallowing difficulty and products available in Australia. There is some overlap between the two books, but each contains unique content. This is a practical book which contains more detail on drug administration via enteral tubes than is readily available elsewhere. Because such administration is generally 'off-label' (outside the approved product information), those prescribing, dispensing or administering drugs via enteral tubes may be liable if the patient experiences adverse effects due to the route or alteration of the product. This makes reliable information on the topic particularly valuable. The handbook would be useful to nurses, pharmacists, doctors and dietitians who regularly deal with patients on enteral feeds.
